Mediolanum International Funds Ltd Buys 9,971 Shares of Gilead Sciences, Inc. $GILD

Mediolanum International Funds Ltd increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 189,803 shares of the biopharmaceutical company’s stock after buying an additional 9,971 shares during the quarter. Mediolanum International Funds Ltd’s holdings in Gilead Sciences were worth $21,376,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of GILD. Rothschild Investment LLC lifted its position in shares of Gilead Sciences by 1.9% during the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock valued at $503,000 after purchasing an additional 84 shares in the last quarter. Hemington Wealth Management increased its stake in Gilead Sciences by 9.3% in the 3rd quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 85 shares during the last quarter. Ignite Planners LLC lifted its position in shares of Gilead Sciences by 1.1% during the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock worth $880,000 after buying an additional 86 shares in the last quarter. Archer Investment Corp boosted its stake in shares of Gilead Sciences by 1.2% in the 2nd quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock worth $807,000 after buying an additional 87 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its holdings in shares of Gilead Sciences by 0.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 34,711 shares of the biopharmaceutical company’s stock valued at $3,912,000 after acquiring an additional 87 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, Director Kelly A. Kramer sold 2,805 shares of the stock in a transaction on Friday, November 28th. The stock was sold at an average price of $127.10, for a total transaction of $356,515.50. Following the sale, the director owned 1,339 shares in the company, valued at $170,186.90. This represents a 67.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the transaction, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at $18,709,027.93. The trade was a 1.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 257,397 shares of company stock worth $33,385,512. Company insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on GILD shares. Royal Bank Of Canada boosted their price objective on Gilead Sciences from $100.00 to $103.00 and gave the stock a “sector perform” rating in a research report on Tuesday, January 20th. Mizuho boosted their price target on shares of Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. HSBC raised their price objective on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a report on Wednesday, December 10th. Wolfe Research boosted their target price on shares of Gilead Sciences from $150.00 to $155.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $135.00 target price on shares of Gilead Sciences in a research report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $136.73.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $141.95 on Friday. The firm has a market capitalization of $176.11 billion, a PE ratio of 22.01, a P/E/G ratio of 0.73 and a beta of 0.33. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The company has a 50-day moving average price of $125.36 and a two-hundred day moving average price of $119.67. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $142.20.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.02 earnings per share. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple sell‑side firms raised targets and reiterated bullish ratings (Wolfe Research to $155/outperform; TD Cowen to $145/buy), reinforcing buy-side momentum and implied upside from current levels. Read More. Read More.
• Positive Sentiment: Broader analyst upgrades/positive notes from Citi, Truist, BMO and UBS add to consensus bullishness, supporting demand and higher valuation multiples. Read More.
• Positive Sentiment: Clinical/regulatory wins for Trodelvy (added to NCCN guidelines; TNBC approval/win coverage) strengthen Gilead’s oncology growth story and revenue optionality beyond antivirals. Read More. Read More.
• Positive Sentiment: Coverage pieces noting that GILD has outperformed the market and is attracting analyst attention can draw momentum and ETF/quant flows into the stock. Read More.
• Neutral Sentiment: Notes on GILD’s presence in Nasdaq/healthcare ETF lineups and elevated investor attention increase volume and liquidity but are not clear directional catalysts by themselves. Read More.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares (~$1.4M) at ~$139.89 (filed on Form 4). While modest relative to his remaining holding and potentially routine, insider sales can be interpreted negatively by some investors. Read More.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.